CovidChloroV1, Main, Exploration, bibRecord, 000C64

SARS-CoV-2 infection among patients with systemic autoimmune diseases.

Identifieur interne : 000C64 ( Main/Exploration ); précédent : 000C63; suivant : 000C65

SARS-CoV-2 infection among patients with systemic autoimmune diseases.

Auteurs : Giacomo Emmi [Italie] ; Alessandra Bettiol [Italie] ; Irene Mattioli [Italie] ; Elena Silvestri [Italie] ; Gerardo Di Scala [Italie] ; Maria Letizia Urban [Italie] ; Augusto Vaglio [Italie] ; Domenico Prisco [Italie]

Source :

Autoimmunity reviews [ 1873-0183 ] ; 2020.

RBID : pubmed:32376395

Descripteurs français

KwdFr :
- Adulte (MeSH), Adulte d'âge moyen (MeSH), Anticorps monoclonaux humanisés (usage thérapeutique), Antirhumatismaux (usage thérapeutique), Betacoronavirus (MeSH), Colchicine (usage thérapeutique), Femelle (MeSH), Hormones corticosurrénaliennes (usage thérapeutique), Humains (MeSH), Hydroxychloroquine (usage thérapeutique), Infections à coronavirus (complications), Italie (MeSH), Maladies auto-immunes (complications), Maladies auto-immunes (traitement médicamenteux), Mâle (MeSH), Pandémies (MeSH), Pneumopathie virale (complications), Sujet âgé (MeSH), Études transversales (MeSH).
MESH :
- traitement médicamenteux : Maladies auto-immunes.
- usage thérapeutique : Anticorps monoclonaux humanisés, Antirhumatismaux, Colchicine, Hormones corticosurrénaliennes, Hydroxychloroquine, Infections à coronavirus, Maladies auto-immunes, Pneumopathie virale.
- Adulte, Adulte d'âge moyen, Betacoronavirus, Femelle, Humains, Italie, Mâle, Pandémies, Sujet âgé, Études transversales.
Wicri :
- geographic : Italie.

English descriptors

KwdEn :
- Adrenal Cortex Hormones (therapeutic use), Adult (MeSH), Aged (MeSH), Antibodies, Monoclonal, Humanized (therapeutic use), Antirheumatic Agents (therapeutic use), Autoimmune Diseases (complications), Autoimmune Diseases (drug therapy), Betacoronavirus (MeSH), COVID-19 (MeSH), Colchicine (therapeutic use), Coronavirus Infections (complications), Cross-Sectional Studies (MeSH), Female (MeSH), Humans (MeSH), Hydroxychloroquine (therapeutic use), Italy (MeSH), Male (MeSH), Middle Aged (MeSH), Pandemics (MeSH), Pneumonia, Viral (complications), SARS-CoV-2 (MeSH).
MESH :
- chemical , therapeutic use : Adrenal Cortex Hormones, Antibodies, Monoclonal, Humanized, Antirheumatic Agents, Colchicine, Hydroxychloroquine.
- geographic : Italy.
- complications : Autoimmune Diseases, Coronavirus Infections, Pneumonia, Viral.
- drug therapy : Autoimmune Diseases.
- Adult, Aged, Betacoronavirus, COVID-19, Cross-Sectional Studies, Female, Humans, Male, Middle Aged, Pandemics, SARS-CoV-2.

Abstract

OBJECTIVES

This study aimed to evaluate the prevalence of clinically overt SARS-CoV-2 infection (COVID-19) among patients with systemic autoimmune diseases residing in Tuscany, and to compare it with that observed in the general Tuscan population.

METHODS

In this cross-sectional study, Tuscan outpatients with systemic autoimmune diseases followed at a tertiary referral centre were telephonically interviewed between April 1st-14th 2020 to collect demographic and clinical data, information on ongoing immunomodulating/immunosuppressive treatments, and on the presence of symptoms suspected of SARS-CoV-2 or of a confirmed infection.

RESULTS

458 patients were interviewed [74% female, median age 56 years (IQR 43-68)]; 56% of them were receiving corticosteroids, 44% traditional disease-modifying anti-rheumatic drugs (DMARDs), of whom 23% hydroxychloroquine, 5% colchicine, while 41% were on biologic DMARDs (of whom 9% on tocilizumab). Thirteen patients reported symptoms suggesting SARS-CoV-2 infection. Of them, 7 had undergone nasopharyngeal swab and only one was positive and developed severe SARS-CoV-2 complications. Within our cohort, the prevalence of SARS-CoV-2 infection was therefore 0.22% (0.01-1.21%), comparable to that observed in the general population of Tuscany [0.20% (0.20-0.21%), p = .597].

CONCLUSIONS

Patients with systemic autoimmune diseases do not seem to carry an increased risk of SARS- CoV-2 infection as compared to the general population.

DOI: 10.1016/j.autrev.2020.102575
PubMed: 32376395
PubMed Central: PMC7200134

Affiliations:

Italie

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 001776
to stream Main, to step Curation: 001776

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">SARS-CoV-2 infection among patients with systemic autoimmune diseases.</title>
<author><name sortKey="Emmi, Giacomo" sort="Emmi, Giacomo" uniqKey="Emmi G" first="Giacomo" last="Emmi">Giacomo Emmi</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Experimental and Clinical Medicine, University of Firenze, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Experimental and Clinical Medicine, University of Firenze</wicri:regionArea>
<wicri:noRegion>University of Firenze</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bettiol, Alessandra" sort="Bettiol, Alessandra" uniqKey="Bettiol A" first="Alessandra" last="Bettiol">Alessandra Bettiol</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Firenze, Italy. Electronic address: alessandra.bettiol@unifi.it.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Firenze</wicri:regionArea>
<wicri:noRegion>University of Firenze</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mattioli, Irene" sort="Mattioli, Irene" uniqKey="Mattioli I" first="Irene" last="Mattioli">Irene Mattioli</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Experimental and Clinical Medicine, University of Firenze, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Experimental and Clinical Medicine, University of Firenze</wicri:regionArea>
<wicri:noRegion>University of Firenze</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Silvestri, Elena" sort="Silvestri, Elena" uniqKey="Silvestri E" first="Elena" last="Silvestri">Elena Silvestri</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Experimental and Clinical Medicine, University of Firenze, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Experimental and Clinical Medicine, University of Firenze</wicri:regionArea>
<wicri:noRegion>University of Firenze</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Di Scala, Gerardo" sort="Di Scala, Gerardo" uniqKey="Di Scala G" first="Gerardo" last="Di Scala">Gerardo Di Scala</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Experimental and Clinical Medicine, University of Firenze, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Experimental and Clinical Medicine, University of Firenze</wicri:regionArea>
<wicri:noRegion>University of Firenze</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Urban, Maria Letizia" sort="Urban, Maria Letizia" uniqKey="Urban M" first="Maria Letizia" last="Urban">Maria Letizia Urban</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Experimental and Clinical Medicine, University of Firenze, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Experimental and Clinical Medicine, University of Firenze</wicri:regionArea>
<wicri:noRegion>University of Firenze</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Vaglio, Augusto" sort="Vaglio, Augusto" uniqKey="Vaglio A" first="Augusto" last="Vaglio">Augusto Vaglio</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Biomedical, Experimental and Clinical Sciences "Mario Serio", University of Firenze, Nephrology and Dialysis Unit, Meyer Children's Hospital, Firenze, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Biomedical, Experimental and Clinical Sciences "Mario Serio", University of Firenze, Nephrology and Dialysis Unit, Meyer Children's Hospital, Firenze</wicri:regionArea>
<wicri:noRegion>Firenze</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Prisco, Domenico" sort="Prisco, Domenico" uniqKey="Prisco D" first="Domenico" last="Prisco">Domenico Prisco</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Experimental and Clinical Medicine, University of Firenze, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Experimental and Clinical Medicine, University of Firenze</wicri:regionArea>
<wicri:noRegion>University of Firenze</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32376395</idno>
<idno type="pmid">32376395</idno>
<idno type="doi">10.1016/j.autrev.2020.102575</idno>
<idno type="pmc">PMC7200134</idno>
<idno type="wicri:Area/Main/Corpus">001776</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001776</idno>
<idno type="wicri:Area/Main/Curation">001776</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001776</idno>
<idno type="wicri:Area/Main/Exploration">001776</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">SARS-CoV-2 infection among patients with systemic autoimmune diseases.</title>
<author><name sortKey="Emmi, Giacomo" sort="Emmi, Giacomo" uniqKey="Emmi G" first="Giacomo" last="Emmi">Giacomo Emmi</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Experimental and Clinical Medicine, University of Firenze, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Experimental and Clinical Medicine, University of Firenze</wicri:regionArea>
<wicri:noRegion>University of Firenze</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bettiol, Alessandra" sort="Bettiol, Alessandra" uniqKey="Bettiol A" first="Alessandra" last="Bettiol">Alessandra Bettiol</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Firenze, Italy. Electronic address: alessandra.bettiol@unifi.it.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Firenze</wicri:regionArea>
<wicri:noRegion>University of Firenze</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mattioli, Irene" sort="Mattioli, Irene" uniqKey="Mattioli I" first="Irene" last="Mattioli">Irene Mattioli</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Experimental and Clinical Medicine, University of Firenze, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Experimental and Clinical Medicine, University of Firenze</wicri:regionArea>
<wicri:noRegion>University of Firenze</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Silvestri, Elena" sort="Silvestri, Elena" uniqKey="Silvestri E" first="Elena" last="Silvestri">Elena Silvestri</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Experimental and Clinical Medicine, University of Firenze, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Experimental and Clinical Medicine, University of Firenze</wicri:regionArea>
<wicri:noRegion>University of Firenze</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Di Scala, Gerardo" sort="Di Scala, Gerardo" uniqKey="Di Scala G" first="Gerardo" last="Di Scala">Gerardo Di Scala</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Experimental and Clinical Medicine, University of Firenze, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Experimental and Clinical Medicine, University of Firenze</wicri:regionArea>
<wicri:noRegion>University of Firenze</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Urban, Maria Letizia" sort="Urban, Maria Letizia" uniqKey="Urban M" first="Maria Letizia" last="Urban">Maria Letizia Urban</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Experimental and Clinical Medicine, University of Firenze, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Experimental and Clinical Medicine, University of Firenze</wicri:regionArea>
<wicri:noRegion>University of Firenze</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Vaglio, Augusto" sort="Vaglio, Augusto" uniqKey="Vaglio A" first="Augusto" last="Vaglio">Augusto Vaglio</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Biomedical, Experimental and Clinical Sciences "Mario Serio", University of Firenze, Nephrology and Dialysis Unit, Meyer Children's Hospital, Firenze, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Biomedical, Experimental and Clinical Sciences "Mario Serio", University of Firenze, Nephrology and Dialysis Unit, Meyer Children's Hospital, Firenze</wicri:regionArea>
<wicri:noRegion>Firenze</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Prisco, Domenico" sort="Prisco, Domenico" uniqKey="Prisco D" first="Domenico" last="Prisco">Domenico Prisco</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Experimental and Clinical Medicine, University of Firenze, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Experimental and Clinical Medicine, University of Firenze</wicri:regionArea>
<wicri:noRegion>University of Firenze</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">Autoimmunity reviews</title>
<idno type="eISSN">1873-0183</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adrenal Cortex Hormones (therapeutic use)</term>
<term>Adult (MeSH)</term>
<term>Aged (MeSH)</term>
<term>Antibodies, Monoclonal, Humanized (therapeutic use)</term>
<term>Antirheumatic Agents (therapeutic use)</term>
<term>Autoimmune Diseases (complications)</term>
<term>Autoimmune Diseases (drug therapy)</term>
<term>Betacoronavirus (MeSH)</term>
<term>COVID-19 (MeSH)</term>
<term>Colchicine (therapeutic use)</term>
<term>Coronavirus Infections (complications)</term>
<term>Cross-Sectional Studies (MeSH)</term>
<term>Female (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Hydroxychloroquine (therapeutic use)</term>
<term>Italy (MeSH)</term>
<term>Male (MeSH)</term>
<term>Middle Aged (MeSH)</term>
<term>Pandemics (MeSH)</term>
<term>Pneumonia, Viral (complications)</term>
<term>SARS-CoV-2 (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte (MeSH)</term>
<term>Adulte d'âge moyen (MeSH)</term>
<term>Anticorps monoclonaux humanisés (usage thérapeutique)</term>
<term>Antirhumatismaux (usage thérapeutique)</term>
<term>Betacoronavirus (MeSH)</term>
<term>Colchicine (usage thérapeutique)</term>
<term>Femelle (MeSH)</term>
<term>Hormones corticosurrénaliennes (usage thérapeutique)</term>
<term>Humains (MeSH)</term>
<term>Hydroxychloroquine (usage thérapeutique)</term>
<term>Infections à coronavirus (complications)</term>
<term>Italie (MeSH)</term>
<term>Maladies auto-immunes (complications)</term>
<term>Maladies auto-immunes (traitement médicamenteux)</term>
<term>Mâle (MeSH)</term>
<term>Pandémies (MeSH)</term>
<term>Pneumopathie virale (complications)</term>
<term>Sujet âgé (MeSH)</term>
<term>Études transversales (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adrenal Cortex Hormones</term>
<term>Antibodies, Monoclonal, Humanized</term>
<term>Antirheumatic Agents</term>
<term>Colchicine</term>
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" type="geographic" xml:lang="en"><term>Italy</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Autoimmune Diseases</term>
<term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Autoimmune Diseases</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Maladies auto-immunes</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticorps monoclonaux humanisés</term>
<term>Antirhumatismaux</term>
<term>Colchicine</term>
<term>Hormones corticosurrénaliennes</term>
<term>Hydroxychloroquine</term>
<term>Infections à coronavirus</term>
<term>Maladies auto-immunes</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Betacoronavirus</term>
<term>COVID-19</term>
<term>Cross-Sectional Studies</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Pandemics</term>
<term>SARS-CoV-2</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Betacoronavirus</term>
<term>Femelle</term>
<term>Humains</term>
<term>Italie</term>
<term>Mâle</term>
<term>Pandémies</term>
<term>Sujet âgé</term>
<term>Études transversales</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Italie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p><b>OBJECTIVES</b>
</p>
<p>This study aimed to evaluate the prevalence of clinically overt SARS-CoV-2 infection (COVID-19) among patients with systemic autoimmune diseases residing in Tuscany, and to compare it with that observed in the general Tuscan population.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>METHODS</b>
</p>
<p>In this cross-sectional study, Tuscan outpatients with systemic autoimmune diseases followed at a tertiary referral centre were telephonically interviewed between April 1st-14th 2020 to collect demographic and clinical data, information on ongoing immunomodulating/immunosuppressive treatments, and on the presence of symptoms suspected of SARS-CoV-2 or of a confirmed infection.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>RESULTS</b>
</p>
<p>458 patients were interviewed [74% female, median age 56 years (IQR 43-68)]; 56% of them were receiving corticosteroids, 44% traditional disease-modifying anti-rheumatic drugs (DMARDs), of whom 23% hydroxychloroquine, 5% colchicine, while 41% were on biologic DMARDs (of whom 9% on tocilizumab). Thirteen patients reported symptoms suggesting SARS-CoV-2 infection. Of them, 7 had undergone nasopharyngeal swab and only one was positive and developed severe SARS-CoV-2 complications. Within our cohort, the prevalence of SARS-CoV-2 infection was therefore 0.22% (0.01-1.21%), comparable to that observed in the general population of Tuscany [0.20% (0.20-0.21%), p = .597].</p>
</div>
<div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b>
</p>
<p>Patients with systemic autoimmune diseases do not seem to carry an increased risk of SARS- CoV-2 infection as compared to the general population.</p>
</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">32376395</PMID>
<DateCompleted><Year>2020</Year>
<Month>06</Month>
<Day>10</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>12</Month>
<Day>18</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-0183</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>19</Volume>
<Issue>7</Issue>
<PubDate><Year>2020</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>Autoimmunity reviews</Title>
<ISOAbbreviation>Autoimmun Rev</ISOAbbreviation>
</Journal>
<ArticleTitle>SARS-CoV-2 infection among patients with systemic autoimmune diseases.</ArticleTitle>
<Pagination><MedlinePgn>102575</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S1568-9972(20)30137-3</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.autrev.2020.102575</ELocationID>
<Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">This study aimed to evaluate the prevalence of clinically overt SARS-CoV-2 infection (COVID-19) among patients with systemic autoimmune diseases residing in Tuscany, and to compare it with that observed in the general Tuscan population.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">In this cross-sectional study, Tuscan outpatients with systemic autoimmune diseases followed at a tertiary referral centre were telephonically interviewed between April 1st-14th 2020 to collect demographic and clinical data, information on ongoing immunomodulating/immunosuppressive treatments, and on the presence of symptoms suspected of SARS-CoV-2 or of a confirmed infection.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">458 patients were interviewed [74% female, median age 56 years (IQR 43-68)]; 56% of them were receiving corticosteroids, 44% traditional disease-modifying anti-rheumatic drugs (DMARDs), of whom 23% hydroxychloroquine, 5% colchicine, while 41% were on biologic DMARDs (of whom 9% on tocilizumab). Thirteen patients reported symptoms suggesting SARS-CoV-2 infection. Of them, 7 had undergone nasopharyngeal swab and only one was positive and developed severe SARS-CoV-2 complications. Within our cohort, the prevalence of SARS-CoV-2 infection was therefore 0.22% (0.01-1.21%), comparable to that observed in the general population of Tuscany [0.20% (0.20-0.21%), p = .597].</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Patients with systemic autoimmune diseases do not seem to carry an increased risk of SARS- CoV-2 infection as compared to the general population.</AbstractText>
<CopyrightInformation>Copyright © 2020 Elsevier B.V. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Emmi</LastName>
<ForeName>Giacomo</ForeName>
<Initials>G</Initials>
<AffiliationInfo><Affiliation>Department of Experimental and Clinical Medicine, University of Firenze, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bettiol</LastName>
<ForeName>Alessandra</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Firenze, Italy. Electronic address: alessandra.bettiol@unifi.it.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Mattioli</LastName>
<ForeName>Irene</ForeName>
<Initials>I</Initials>
<AffiliationInfo><Affiliation>Department of Experimental and Clinical Medicine, University of Firenze, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Silvestri</LastName>
<ForeName>Elena</ForeName>
<Initials>E</Initials>
<AffiliationInfo><Affiliation>Department of Experimental and Clinical Medicine, University of Firenze, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Di Scala</LastName>
<ForeName>Gerardo</ForeName>
<Initials>G</Initials>
<AffiliationInfo><Affiliation>Department of Experimental and Clinical Medicine, University of Firenze, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Urban</LastName>
<ForeName>Maria Letizia</ForeName>
<Initials>ML</Initials>
<AffiliationInfo><Affiliation>Department of Experimental and Clinical Medicine, University of Firenze, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Vaglio</LastName>
<ForeName>Augusto</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Department of Biomedical, Experimental and Clinical Sciences "Mario Serio", University of Firenze, Nephrology and Dialysis Unit, Meyer Children's Hospital, Firenze, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Prisco</LastName>
<ForeName>Domenico</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Department of Experimental and Clinical Medicine, University of Firenze, Italy.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>05</Month>
<Day>05</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>Autoimmun Rev</MedlineTA>
<NlmUniqueID>101128967</NlmUniqueID>
<ISSNLinking>1568-9972</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000305">Adrenal Cortex Hormones</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018501">Antirheumatic Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber>
<NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>I031V2H011</RegistryNumber>
<NameOfSubstance UI="C502936">tocilizumab</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>SML2Y3J35T</RegistryNumber>
<NameOfSubstance UI="D003078">Colchicine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Autoimmun Rev. 2020 Oct;19(10):102639</RefSource>
<PMID Version="1">32801048</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000305" MajorTopicYN="N">Adrenal Cortex Hormones</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018501" MajorTopicYN="N">Antirheumatic Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001327" MajorTopicYN="N">Autoimmune Diseases</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003078" MajorTopicYN="N">Colchicine</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007558" MajorTopicYN="N" Type="Geographic">Italy</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword>
<Keyword MajorTopicYN="N">Hydroxychloroquine</Keyword>
<Keyword MajorTopicYN="N">Immunosuppressants</Keyword>
<Keyword MajorTopicYN="N">Systemic autoimmune diseases</Keyword>
<Keyword MajorTopicYN="N">Tocilizumab</Keyword>
</KeywordList>
<CoiStatement>Declaration of Competing Interest None declared.</CoiStatement>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>04</Month>
<Day>22</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>04</Month>
<Day>23</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>5</Month>
<Day>8</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>6</Month>
<Day>11</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>5</Month>
<Day>8</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32376395</ArticleId>
<ArticleId IdType="pii">S1568-9972(20)30137-3</ArticleId>
<ArticleId IdType="doi">10.1016/j.autrev.2020.102575</ArticleId>
<ArticleId IdType="pmc">PMC7200134</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>JAMA. 2020 Mar 23;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32203977</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Apr 30;382(18):1708-1720</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32109013</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Rheumatol. 2020 Jun;16(6):293-294</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32242121</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Rheum Dis. 2020 Jun;79(6):839-840</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32205336</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Regul Homeost Agents. 2020 Apr 07;34(2):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32253888</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Intern Med. 2020 Jun 2;172(11):754-755</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32232419</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Autoimmun Rev. 2020 May;19(5):102523</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32205186</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Rheum Dis. 2020 May;79(5):667-668</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32241793</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect. 2020 Jun;80(6):607-613</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32283152</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Rheumatol. 2020 Apr 16;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32309814</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Mar 28;395(10229):1033-1034</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32192578</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Rheumatol. 2020 Apr 10;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32277367</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Exp Rheumatol. 2018 Mar-Apr;36(2):317-328</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29303710</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Apr 4;395(10230):1110-1111</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32220279</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Gastroenterol Hepatol. 2020 Jun;5(6):532-533</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32278366</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Italie</li>
</country>
</list>
<tree><country name="Italie"><noRegion><name sortKey="Emmi, Giacomo" sort="Emmi, Giacomo" uniqKey="Emmi G" first="Giacomo" last="Emmi">Giacomo Emmi</name>
</noRegion>
<name sortKey="Bettiol, Alessandra" sort="Bettiol, Alessandra" uniqKey="Bettiol A" first="Alessandra" last="Bettiol">Alessandra Bettiol</name>
<name sortKey="Di Scala, Gerardo" sort="Di Scala, Gerardo" uniqKey="Di Scala G" first="Gerardo" last="Di Scala">Gerardo Di Scala</name>
<name sortKey="Mattioli, Irene" sort="Mattioli, Irene" uniqKey="Mattioli I" first="Irene" last="Mattioli">Irene Mattioli</name>
<name sortKey="Prisco, Domenico" sort="Prisco, Domenico" uniqKey="Prisco D" first="Domenico" last="Prisco">Domenico Prisco</name>
<name sortKey="Silvestri, Elena" sort="Silvestri, Elena" uniqKey="Silvestri E" first="Elena" last="Silvestri">Elena Silvestri</name>
<name sortKey="Urban, Maria Letizia" sort="Urban, Maria Letizia" uniqKey="Urban M" first="Maria Letizia" last="Urban">Maria Letizia Urban</name>
<name sortKey="Vaglio, Augusto" sort="Vaglio, Augusto" uniqKey="Vaglio A" first="Augusto" last="Vaglio">Augusto Vaglio</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C64 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000C64 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidChloroV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:32376395
   |texte=   SARS-CoV-2 infection among patients with systemic autoimmune diseases.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:32376395" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidChloroV1

This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021

	Serveur d'exploration COVID et hydrochloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration COVID et hydrochloroquine

SARS-CoV-2 infection among patients with systemic autoimmune diseases.

SARS-CoV-2 infection among patients with systemic autoimmune diseases.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki